Researcher Profiles

Return to member profile

Mark N. Stein, MD

Publications since 2011

Cui, R. Yue, W. Lattime, E. C. Stein, M. N. Xu, Q. Tan, X. L. Targeting tumor-associated macrophages to combat pancreatic cancer. Oncotarget, In process, . (PMID: 27191744)

Agarwal, N. Machiels, J. P. Suarez, C. Lewis, N. Higgins, M. Wisinski, K. Awada, A. Maur, M. Stein, M. Hwang, A. Mosher, R. Wasserman, E. Wu, G. Zhang, H. Zieba, R. Elmeliegy, M. Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer. Oncologist, In process, . (PMID: 27091421)

McKay, R. R. Zurita, A. J. Werner, L. Bruce, J. Y. Carducci, M. A. Stein, M. N. Heath, E. I. Hussain, A. Tran, H. T. Sweeney, C. J. Ross, R. W. Kantoff, P. W. Slovin, S. F. Taplin, M. E. A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy. J Clin Oncol, In process, . (PMID: 27044933)

Stein, M. N. Jang, T. L. Striving Toward a Cure for Prostate Cancer. J Clin Oncol, In process, . (PMID: 27022121)

Armstrong, A. J. Halabi, S. Healy, P. Lee, W. R. Koontz, B. F. Moul, J. W. Mundy, K. Creel, P. Wood, S. Davis, K. Carducci, M. A. Stein, M. Hobbs, C. Reimer, B. Nguyen, M. Anand, M. Bratt, L. Kim, S. Tran, P. T. George, D. J. A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy. Prostate Cancer Prostatic Dis, 19:100-106, . (PMID: 26754260)

Scher, H. I. Morris, M. J. Stadler, W. M. Higano, C. Basch, E. Fizazi, K. Antonarakis, E. S. Beer, T. M. Carducci, M. A. Chi, K. N. Corn, P. G. de Bono, J. S. Dreicer, R. George, D. J. Heath, E. I. Hussain, M. Kelly, W. K. Liu, G. Logothetis, C. Nanus, D. Stein, M. N. Rathkopf, D. E. Slovin, S. F. Ryan, C. J. Sartor, O. Small, E. J. Smith, M. R. Sternberg, C. N. Taplin, M. E. Wilding, G. Nelson, P. S. Schwartz, L. H. Halabi, S. Kantoff, P. W. Armstrong, A. J. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol, In process, . (PMID: 26903579)

Amin, M. Minton, S. E. LoRusso, P. M. Krishnamurthi, S. S. Pickett, C. A. Lunceford, J. Hille, D. Mauro, D. Stein, M. N. Wang-Gillam, A. Trull, L. Lockhart, A. C. A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors. Invest New Drugs, In process, . (PMID: 26620496)

Stein, M. N. Hussain, M. Stadler, W. M. Liu, G. Tereshchenko, I. V. Goodin, S. Jeyamohan, C. Kaufman, H. L. Mehnert, J. DiPaola, R. S. A Phase II Study of AT-101 to Overcome Bcl-2-Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer. Clin Genitourin Cancer, In process, . (PMID: 26476589)

Vaishampayan, U. Shevrin, D. Stein, M. Heilbrun, L. Land, S. Stark, K. Li, J. Dickow, B. Heath, E. Smith, D. Fontana, J. Phase II trial of carboplatin, everolimus and prednisone in metastatic castrate resistant prostate cancer pretreated with docetaxel chemotherapy: A Prostate Cancer Clinical Trial Consortium Study. Urology, In process, . (PMID: 26375845)

Pal, S. K. Choueiri, T. K. Wang, K. Khaira, D. Karam, J. A. Van Allen, E. Palma, N. A. Stein, M. N. Johnson, A. Squillace, R. Elvin, J. A. Chmielecki, J. Yelensky, R. Yakirevich, E. Lipson, D. Lin, D. I. Miller, V. A. Stephens, P. J. Ali, S. M. Ross, J. S. Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling. Eur Urol, In process, . (PMID: 26149668)

Bansal, N. Mishra, P. J. Stein, M. DiPaola, R. S. Bertino, J. R. Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells. Oncotarget, In process, . (PMID: 26036314)

DiPaola, R. S. Chen, Y. Bubley, G. J. Stein, M. N. Hahn, N. M. Carducci, M. A. Lattime, E. C. Gulley, J. L. Arlen, P. M. Butterfield, L. H. Wilding, G. A National Multicenter Phase 2 Study of Prostate-specific Antigen (PSA) Pox Virus Vaccine with Sequential Androgen Ablation Therapy in Patients with PSA Progression: ECOG 9802. Eur Urol, In process, . (PMID: 25533418)

Freedland, S. J. Rumble, R. B. Finelli, A. Chen, R. C. Slovin, S. Stein, M. N. Mendelson, D. S. Wackett, C. Sandler, H. M. Adjuvant and Salvage Radiotherapy After Prostatectomy: American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol, 32:3892-3898, . (PMID: 25366677)

Tereshchenko, I. V. Zhong, H. Chekmareva, M. A. Kane-Goldsmith, N. Santanam, U. Petrosky, W. Stein, M. N. Ganesan, S. Singer, E. A. Moore, D. Tischfield, J. A. DiPaola, R. S. ERG and CHD1 heterogeneity in prostate cancer: Use of confocal microscopy in assessment of microscopic foci. Prostate, 74:1551-1559, . (PMID: 25175909, PMCID: PMC4181586)

Stein, M. N. Hirshfield, K. M. Zhong, H. Singer, E. A. Ali, S. M. Ganesan, S. Response to Crizotinib in a Patient with MET-mutant Papillary Renal Cell Cancer After Progression on Tivantinib. Eur Urol, In process, . (PMID: 25457019)

DiCosimo, S. Sathyanarayanan, S. Bendell, J. C. Cervantes, A. Stein, M. Brana, I. Roda Perez, D. Haines, B. B. Zhang, T. Winter, C. Jha, S. Xu, Y. Frazier, J. Klinghofer, R. Leighton-Swayze, A. Song, Y. Ebbinghaus, S. Baselga, J. Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial. Clin Cancer Res, In process, . (PMID: 25320355)

Stein, M. N. Patel, N. Bershadskiy, A. Sokoloff, A. Singer, E. A. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl, 16:387-400, . (PMID: 24759590, PMCID: PMC4023364)

Tan, A. R. Dowlati, A. Stein, M. N. Jones, S. F. Infante, J. R. Bendell, J. Kane, M. P. Levinson, K. T. Suttle, A. B. Burris Iii, H. A. Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies. Br J Cancer, 110:2647-2654, . (PMID: 24800949, PMCID: PMC4037836)

Bruce, J. Y. Kolesar, J. M. Hammers, H. Stein, M. N. Carmichael, L. Eickhoff, J. Johnston, S. A. Binger, K. A. Heideman, J. L. Perlman, S. B. Jeraj, R. Liu, G. A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies. Cancer Chemother Pharmacol, 73:485-493, . (PMID: 24414551, PMCID: PMC4200479)

Bansal, N. Davis, S. Tereshchenko, I. Budak-Alpdogan, T. Zhong, H. Stein, M. N. Kim, I. Y. Dipaola, R. S. Bertino, J. R. Sabaawy, H. E. Enrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion. Prostate, 74:187-200, . (PMID: 24154958, PMCID: PMC3939797)

Tan, A. R. Gibbon, D. G. Stein, M. N. Lindquist, D. Edenfield, J. W. Martin, J. C. Gregory, C. Suttle, A. B. Tada, H. Botbyl, J. Stephenson, J. J. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. Cancer Chemother Pharmacol, 71:1635-1643, . (PMID: 23636448)

Lee, J. H. Stein, M. Roychowdhury, S. Percutaneous treatment of a sacral metastasis with combined embolization, cryoablation, alcohol ablation and sacroplasty for local tumor and pain control. Interv Neuroradiol, 19:250-253, . (PMID: 23693052, PMCID: PMC3670067)

Shao, Y. H. Kim, S. Moore, D. F. Shih, W. Lin, Y. Stein, M. Kim, I. Y. Lu-Yao, G. L. Cancer-specific Survival After Metastasis Following Primary Radical Prostatectomy Compared with Radiation Therapy in Prostate Cancer Patients: Results of a Population-based, Propensity Score-Matched Analysis. Eur Urol, In process, . (PMID: 23759328)

Raez, L. E. Papadopoulos, K. Ricart, A. D. Chiorean, E. G. Dipaola, R. S. Stein, M. N. Rocha Lima, C. M. Schlesselman, J. J. Tolba, K. Langmuir, V. K. Kroll, S. Jung, D. T. Kurtoglu, M. Rosenblatt, J. Lampidis, T. J. A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol, 71:523-530, . (PMID: 23228990)

Yue, J. Lu, H. Lan, S. Liu, J. Stein, M. N. Haffty, B. G. Shen, Z. Identification of the DNA repair defects in a case of dubowitz syndrome. PLoS One, 8:e54389, . (PMID: 23372718, PMCID: PMC3556036)

Choueiri, T. K. Vaishampayan, U. Rosenberg, J. E. Logan, T. F. Harzstark, A. L. Bukowski, R. M. Rini, B. I. Srinivas, S. Stein, M. N. Adams, L. M. Ottesen, L. H. Laubscher, K. H. Sherman, L. McDermott, D. F. Haas, N. B. Flaherty, K. T. Ross, R. Eisenberg, P. Meltzer, P. S. Merino, M. J. Bottaro, D. P. Linehan, W. M. Srinivasan, R. Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma. J Clin Oncol, In process, . (PMID: 23213094)

Saleem, A. Dvorzhinski, D. Santanam, U. Mathew, R. Bray, K. Stein, M. White, E. Dipaola, R. S. Effect of dual inhibition of apoptosis and autophagy in prostate cancer. Prostate, 72:1374-1381, . (PMID: 22241682)

Lin, H. Gounder, M. K. Bertino, J. R. Kong, A. N. DiPaola, R. S. Stein, M. N. A validated HPLC assay for the determination of R-(-)-gossypol in human plasma and its application in clinical pharmacokinetic studies. J Pharm Biomed Anal, 66:371-375, . (PMID: 22483642, PMCID: PMC3358459)

Holen, K. Dipaola, R. Liu, G. Tan, A. R. Wilding, G. Hsu, K. Agrawal, N. Chen, C. Xue, L. Rosenberg, E. Stein, M. A phase I trial of MK-0731, a Kinesin Spindle Protein (KSP) inhibitor, in patients with solid tumors. Invest New Drugs, 30:1088-1095, . (PMID: 21424701, PMCID: PMC3394096)

Gounder, M. K. Lin, H. Stein, M. Goodin, S. Bertino, J. R. Kong, A. N. DiPaola, R. S. A validated bioanalytical HPLC method for pharmacokinetic evaluation of 2-deoxyglucose in human plasma. Biomed Chromatogr, 26:650-654, . (PMID: 21932382)

Stein, M. Goodin, S. Doyle-Lindrud, S. Silberberg, J. Kane, M. Metzger, D. Eddy, S. Shih, W. DiPaola, R. S. Transdermal estradiol in castrate and chemotherapy resistant prostate cancer. Med Sci Monit, 18:CR260-CR264, . (PMID: 22460098)

Stein, M. N. Goodin, S. Dipaola, R. S. Abiraterone in prostate cancer: a new angle to an old problem. Clin Cancer Res, 18:1848-1854, . (PMID: 22451619)

Saraiya, B. Chugh, R. Karantza, V. Mehnert, J. Moss, R. A. Savkina, N. Stein, M. N. Baker, L. H. Chenevert, T. Poplin, E. A. Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors. Invest New Drugs, 30:258-265, . (PMID: 20697775)

Bray, K. Mathew, R. Lau, A. Kamphorst, J. J. Fan, J. Chen, J. Chen, H. Y. Ghavami, A. Stein, M. Dipaola, R. S. Zhang, D. Rabinowitz, J. D. White, E. Autophagy Suppresses RIP Kinase-Dependent Necrosis Enabling Survival to mTOR Inhibition. PLoS One, 7:e41831, . (PMID: 22848625, PMCID: PMC3406086)

Bradley, D. A. Daignault, S. Ryan, C. J. Dipaola, R. S. Smith, D. C. Small, E. Gross, M. E. Stein, M. N. Chen, A. Hussain, M. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Invest New Drugs, 29:1432-1440, . (PMID: 20336348, PMCID: PMC2917503)

Mehnert, J. M. Tan, A. R. Moss, R. Poplin, E. Stein, M. N. Sovak, M. Levinson, K. Lin, H. Kane, M. Gounder, M. Lin, Y. Shih, W. J. White, E. Rubin, E. H. Karantza, V. Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach. Mol Cancer Ther, 10:1509-1519, . (PMID: 21680752, PMCID: PMC3155243)

Liu, G. Chen, Y. H. Kolesar, J. Huang, W. Dipaola, R. Pins, M. Carducci, M. Stein, M. Bubley, G. J. Wilding, G. Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer(,). Urol Oncol, In process, . (PMID: 21784672, PMCID: PMC3223557)

Roberts, C. B. Albertsen, P. C. Shao, Y. H. Moore, D. F. Mehta, A. R. Stein, M. N. Lu-Yao, G. L. Patterns and correlates of prostate cancer treatment in older men. Am J Med, 124:235-243, . (PMID: 21396507)

Rini, B. I. Stein, M. Shannon, P. Eddy, S. Tyler, A. Stephenson, J. J. Jr Catlett, L. Huang, B. Healey, D. Gordon, M. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer, 117:758-767, . (PMID: 20922784)

Burris, H. Stephenson, J. Otterson, G. A. Stein, M. McGreivy, J. Sun, Y. N. Ingram, M. Ye, Y. Schwartzberg, L. S. Safety and pharmacokinetics of motesanib in combination with panitumumab and gemcitabine-Cisplatin in patients with advanced cancer. J Oncol, 2011:853931, . (PMID: 21559248, PMCID: PMC3087488)